Advertisement

Topics

Bayer's PI3K inhibitor secures FDA approval

06:03 EDT 15 Sep 2017 | BioPharmaDive

The regulatory OK was supported by a mid-stage study which showed efficacy in heavily pretreated patients with follicular lymphoma.

Original Article: Bayer's PI3K inhibitor secures FDA approval

NEXT ARTICLE

More From BioPortfolio on "Bayer's PI3K inhibitor secures FDA approval"

Quick Search
Advertisement